期刊文献+

前列腺癌筛查专家共识 被引量:73

Consensus of prostate cancer screening
原文传递
导出
摘要 我国前列腺癌发病率呈逐年上升趋势,初诊的前列腺癌患者临床分期较晚,总体预后差.对高危人群进行筛查、早期诊断和治疗是提高我国前列腺癌患者总体生存率的手段.为规范前列腺癌筛查的方法,中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组讨论并形成了相关专家共识.共识认为:前列腺癌筛查可以增加前列腺癌的检出率,发现早期前列腺癌;对预期寿命10年以上的男性和前列腺癌高危人群定期进行血清前列腺特异性抗原检测. The incidence of prostate cancer is increasing rapidly in China,the clinical stage of prostate cancer patients is comparatively late and the overall survival rate is inferior to that reported in the developed countries.Prostate cancer screening is an effective measure to reduce the risk of death through early detection.In order to identify the best way of prostate cancer screening in China,the Chinese AntiCancer Association Genitourinary Cancer Committee Prostate Cancer Working Group reviewed all published data concerning the benefits and harms of screening for prostate caner and created the consensus.The consensus include the following points:screening asymptomatic men for prostate cancer by prostate specific antigen (PSA)testing in the general population is the potential measure to reduce mortality rates through early detection,PSA testing should be offered earlier in men with life expectancy over 10 years and men at high risk of prostate cancer.
出处 《中华外科杂志》 CAS CSCD 北大核心 2017年第5期340-342,共3页 Chinese Journal of Surgery
关键词 前列腺肿瘤 筛查 Prostate neoplasms Screening
  • 相关文献

参考文献5

二级参考文献32

  • 1邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 2叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 3Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55:74-108.
  • 4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56:106-130.
  • 5Michael PM, Bernard D, Kaill M, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol, 2005, 174:1794-1797.
  • 6Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol, 2004, 172 : 1822-1827.
  • 7Benaim EA, Pace CM, Roehrbor CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urel, 2002, 42:12-17.
  • 8Benaim EA, Pace CM, Lam PM, et al. Nadir PSA as a progression to androgeindependent prostate cancer. Urology, 2002, 59:73-77.
  • 9Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LRH analogue (Zoladex). Br J Urol, 1986, 58:676-679.
  • 10Mulders PF, Fernandez del MP, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol, 1992, 21:2-7.

共引文献1121

同被引文献609

引证文献73

二级引证文献341

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部